2-Arachidonoylglycerol: An Endogenous Cannabinoid Receptor Agonist

Author(s):  
T. Sugiura ◽  
K. Waku
Life Sciences ◽  
2011 ◽  
Vol 88 (15-16) ◽  
pp. 653-657 ◽  
Author(s):  
Gláucia Maria Lopes Reis ◽  
Marina Abadia Ramos ◽  
Daniela da Fonseca Pacheco ◽  
André Klein ◽  
Andréa Castro Perez ◽  
...  

1998 ◽  
Vol 355 (1) ◽  
pp. 57-66 ◽  
Author(s):  
Peter W. Stengel ◽  
Marian K. Rippy ◽  
Sandra L. Cockerham ◽  
William A. Devane ◽  
Steven A. Silbaugh

FEBS Letters ◽  
1996 ◽  
Vol 393 (2-3) ◽  
pp. 231-235 ◽  
Author(s):  
Christian C. Felder ◽  
Amie Nielsen ◽  
Eileen M. Briley ◽  
Miklós Palkovits ◽  
Joseph Priller ◽  
...  

2019 ◽  
Vol 16 (10) ◽  
pp. 1167-1174 ◽  
Author(s):  
Kamil J. Kuder ◽  
Tadeusz Karcz ◽  
Maria Kaleta ◽  
Katarzyna Kiec-Kononowicz

Background: : One of the best known to date GPCR class A (Rhodopsin) includes more than 100 orphan receptors for which the endogenous ligand is not known or is unclear. One of them is N-arachidonyl glycine receptor, named GPR18, a receptor that has been reported to be activated by Δ9-THC, endogenous cannabinoid receptors agonist anandamide and other cannabinoid receptor ligands suggesting it could be considered as third cannabinoid receptor. GPR18 activity, as well as its distribution might suggest usage of GPR18 ligands in treatment of endometriosis, cancer, and neurodegenerative disorders. Yet, so far only few GPR18 antagonists have been described, thus only ligand-based design approaches appear to be most useful to identify new ligands for this orphan receptor. Methods: : Main goal of this study, GPR18 inactive form homology model was built on the basis of the evolutionary closest homologous template: Human P2Y1 Receptor crystal structure. Results: : Obtained model was further evaluated and showed active/nonactive ligands differentiating properties with acceptable confidence. Moreover, it allowed for preliminary assessment of proteinligand interactions for a set of previously described ligands. Conclusion:: Thus collected data might serve as a starting point for a discovery of novel, active GPR18 blocking ligands.


Life Sciences ◽  
2009 ◽  
Vol 85 (9-10) ◽  
pp. 351-356 ◽  
Author(s):  
Gláucia Maria Lopes Reis ◽  
Daniela Pacheco ◽  
Andréa Castro Perez ◽  
André Klein ◽  
Marina Abadia Ramos ◽  
...  

Sign in / Sign up

Export Citation Format

Share Document